期刊文献+

正交试验优选羧甲基壳聚糖-醋甲唑胺纳米微球的制备方案 被引量:4

Otimization on preparation technology of carboxymethyl chitosan-methazolamide nanoparticles by orthogonal design
在线阅读 下载PDF
导出
摘要 目的:制备羧甲基壳聚糖载药纳米微球,醋甲唑胺为模型药物,测量药物的包封率和纳米微球形态。方法:采用乳化交联法,在微乳液的基础上制备载药纳米微球,对可能影响药物包封率的处方因素进行优化设计,筛选出最优配方。结果:羧甲基壳聚糖溶液的浓度对包封率有显著性影响,三聚磷酸钠溶液浓度和醋甲唑胺药量对包封率未见影响。优化方案的载药纳米微球包封率为49.36%,其电镜下为较规整的球型纳米微球,平均粒径386.0 nm。结论:采用乳化交联法,可形成较高包封率的羧甲基壳聚糖-醋甲唑胺纳米微球。 Objective: To prepare carboxymethyl chitosan (CMC) drug - loaded nanoparticles, with methazolamide as model drug. The drug encapsulation efficiency and morphology should be measured. Methods : Drug - loaded nanoparticles were preparated in microemulsion by emulsion crosslinking method. The design of formulation factors that may affect the drug entrapment efficiency was optimized to select optimal formulation. Results : The concentration of carboxymethyl chitosan solution has a significant effect on the entrapment efficiency, when sodium tripolyphosphate (TPP) solution concentration and weight of methazolamide don' t effect on the entrapment efficiency. Entrapment efficiency of optimization of drug - Loaded nanoparticles was 49.36%. The nanoparticles is regular and baLL - type, with average particle size in 386.0 nm on electron microscope. Conclusion: Nanoparticles can be formated with hydrophilic carboxymethyl - chitosan coating lipophilic methazolamide by emulsion crosslinking method, and high encapsulation efficiency can be achieved.
出处 《天津药学》 2014年第2期10-13,共4页 Tianjin Pharmacy
基金 天津市卫生局科技基金(青年)项目(No.2012KY34)
关键词 羧甲基壳聚糖 纳米微球 醋甲唑胺 乳化交联 carboxymethyl - chitosan, nanoparticles, methazolamide, emulsion crosslinking
  • 相关文献

参考文献8

二级参考文献35

  • 1廖华萍,王玲.视网膜静脉阻塞的治疗进展[J].国际眼科杂志,2005,5(3):537-542. 被引量:37
  • 2刘爱明,李伟,杨菊林,王本敏.RP-HPLC测定兔眼房水中环孢素浓度[J].中国药师,2005,8(9):745-746. 被引量:4
  • 3陈滨,姚克,张惠成,胡勇平,钟建光,王聪.两种不同剂型毛果芸香碱滴眼液在兔眼房水中的药代动力学[J].眼科研究,2005,23(5):552-552. 被引量:2
  • 4张惠蓉,王欣,鹿新荣,杨艳芳,刘峰.视网膜静脉阻塞致黄斑水肿患者相干光断层扫描和视力预后观察[J].中华眼科杂志,2005,41(10):910-916. 被引量:45
  • 5DAVID MB,TIMPTHY MH,JONAS DR,et al. Frequency of restenosis after balloon pulmonary arterioplasty and its causes [J]. Am J Cardiol,2000,86( 11 ) :1205 -1209.
  • 6MARC H, ULRICH S,JOSEF N. Fighting restenosis after coronary angioplasty: contemporary and future treatment options[ J ]. Int J Cardiol,2002,83 ( 3 ) : 199 - 205.
  • 7TJEBBE HJ,GUSSENHOVEN RHM,VAN SJ,et al. Effect of Simvastatinon restenosis after percutaneous transluminal angioplasty of femoropopliteal arterial obstruction[ J]. Am J Cardiol,2000,86 ( 7 ) : 774 - 776.
  • 8WHITLOW PL, BASS TA, KIPPERMAN RM, et al. Results of the study to determine otablator and transluminal angioplasty strategy [ J ]. Am J Cardiol,2001,87 ( 6 ) : 699 - 705.
  • 9TANOUS D,BRASEN JH ,CHOY K,et al. Probucol inhibits in - stent thrombosis and neointimal hyperplasia by promoting re-endothelialization [ J ]. Atherosclerosis, 2006,189 ( 2 ) : 342 - 349.
  • 10HONG SC,ZHAO SP,LIU Q,et al. Effect of the anti-oxidant probucol on soluble thrombomodulin in hypercholesterolemic rabbits[J]. Int J Cardiol,2008,123(2):180-182.

共引文献53

同被引文献45

  • 1刘雪霞,汪东生.青光眼白内障联合术后黄斑水肿一例[J].中华眼科医学杂志(电子版),2013,3(3):158-159. 被引量:1
  • 2陈炯,韩春茂,余朝恒.纳米银用于烧伤患者创面后银代谢的变化[J].中华烧伤杂志,2004,20(3):161-163. 被引量:56
  • 3杨飏高,殿文.醋甲唑胺治疗青光眼的临床研究[J].辽宁医学杂志,2005,19(3):156-157. 被引量:5
  • 4国家质量监督检验检疫总局,中国国家标准化管理委员会.医疗器械生物学评价[S].GB/T16886,10.北京:中国标准出版社,2005.
  • 5CALVO P, VILA-JATO JL,ALONSO MJ. Comparative in vitro e- valuation of several colloidal system,nanoparticles and nanoemul- sion,as ocular drug carriers [ J]. J Pharm Scl, 1996,85 ( 5 ) : 530 - 536.
  • 6SHEN J,WANG Y,PING QN,et al. Mucoadhesive effect of thio- lated PEG stearate and its modified NLC for ocular drug delivery [ J]. J Control Release,2009,137 ( 3 ) :217 - 223.
  • 7COLO GD, ZAMBITO Y, BURGALASSI S, et al. Effect of chi- tosan and of N-carboxymethylchitosan onintraocular penetration of topically applied ofloxacin [ J ]. Int J Pharm,2004,273 ( 1 - 2) :37 -44.
  • 8MOTWANI SK,CHOPRA S,TALEGAONKAR S. Chitosan-sodi- um alginate nanopartieles as submieroseopie reservoirs for oeular delivery: formulation, optimisation and in vitro eharaeterisation [ J ]. Eur J Pharm Biopharm ,2007,68 (3) :513 - 525.
  • 9Sim RW, Nic GC, Pro J, et al. Efficacy and safety of oral methazolamide in patients with type 2 diabetes: a 24-week, placebo-controlled, double-blind study [J]. Diabetes Care, 2014, 37 (11): 3121-3123.
  • 10Fossati S, Giannoni P. The carbonic anhydrase inhibitor methazolamide prevents amyloid beta induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain[J]. Neurobiol Dis,2016, 86:29-40.

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部